High "on Treatment" Platelet Reactivity in the Intensive Care Unit
Study Details
Study Description
Brief Summary
High "on treatment" platelet reactivity is defined as a poor pharmacodynamic response to the administration of acetylsalicylic acid or clopidogrel. acetylsalicylic acid and clopidogrel are drugs commonly used to reduce platelet activity and prevent cardiovascular events. High "on treatment" platelet reactivity is associated with a higher cardiovascular event rate.
Ticagrelor and prasugrel, like clopidogrel both P2Y12 inhibitors are effective in treating patients with High "on treatment" platelet reactivity to clopidogrel.
Critically ill patients are a unique population with altered pharmacokinetic and pharmacodynamic properties. Gastrointestinal dysmotility with associated altered resorption and impaired microvascular function occur frequently in critically ill patients and may lead to altered resorption of orally administered drugs.
The investigators will test a minimum of 100 patients treated with 100mg acetylsalicylic acid per os and 100 patients treated with 75mg clopidogrel per os to calculate the prevalence of high "on treatment" platelet reactivity.
30 patients with high "on treatment" platelet reactivity to acetylsalicylic acid will be randomized to three new treatment groups. In the first group patients will receive 200mg acetylsalicylic acid per os, in the second group 100mg acetylsalicylic acid intravenously and in the third group 81mg chewable acetylsalicylic acid. Each group will contain 10 patients. Pharmacokinetics and pharmacodynamics will be reassessed to evaluate the new treatment.
36 patients with high "on treatment" platelet reactivity to clopidogrel will be randomized to receive either an additional loading dose of 600mg clopidogrel (n=24) or to continue normal treatment as a control group (n=12). Pharmacokinetics and pharmacodynamics will be reassessed and those patients, who are tested again to have high "on treatment" platelet reactivity in spite of the additional loading dose, will now be randomized to receive either ticagrelor or prasugrel. The investigators expect about six patients per group. The twelve patients in the control group will continue normal treatment (75mg/day) until the end of the study. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel will be assessed. Any patient, who is tested again with high "on treatment" platelet reactivity in spite of receiving prasugrel or ticagrelor, will be finally switched to the opposite drug and a final high "on treatment" platelet reactivity testing will be conducted.
16 patients who are treated with 10mg prasugrel per os will be tested for HTPR and if positively tested will be switched to 2x90mg ticagrelor per os per day. Platelet reactivity will be reassessed to test whether switching the medication benefits the patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 200mg acetylsalicylic acid per os patients with high "on treatment" platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os |
Drug: acetylsalicylic acid
Other Names:
|
| Experimental: 100mg acetylsalicylic acid intravenous patients with high "on treatment" platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously. |
Drug: acetylsalicylic acid
Other Names:
|
| Experimental: 81 mg chewable acetylsalicylic acid patients with high "on treatment" platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid |
Drug: acetylsalicylic acid
Other Names:
|
| Active Comparator: 75mg clopidogrel control group for patients with high "on treatment" platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day |
Drug: clopidogrel
Other Names:
|
| Experimental: 60mg prasugrel Loading dose of prasugrel for patients who remain tested with high "on treatment" platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel |
Drug: prasugrel
Other Names:
|
| Experimental: 600mg clopidogrel additional loading dose for 24 patients tested with high "on treatment" platelet reactivity to clopidogrel |
Drug: clopidogrel
Other Names:
|
| Experimental: 180mg ticagrelor Loading dose of ticagrelor for patients who remain tested with high "on treatment" platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high "on treatment" platelet reactivity after being treated with 10mg prasugrel daily |
Drug: ticagrelor
Other Names:
|
| Active Comparator: prasugrel 10mg patients treated with 10mg prasugrel daily |
Drug: prasugrel
Other Names:
|
Outcome Measures
Primary Outcome Measures
- pharmacodynamics (Arachidonic acid induced aggregation test with multiplate electrode aggregometry) [on average 3 days]
Arachidonic acid induced aggregation test with multiplate electrode aggregometry of patients with high "on treatment" platelet reactivity to acetylsalicylic acid after receiving new treatments as explained. adenosine diphosphate induced aggregation tested with multiplate electrode aggregometry of patients with high "on treatment" platelet reactivity to clopidogrel after an additional loading dose clopidogrel, or after receiving prasugrel or ticagrelor
Secondary Outcome Measures
- Prevalence of high "on-treatment" platelet reactivity in the intensive care unit [maximum 2 weeks after admission]
percentage of patients tested with high "on treatment" platelet reactivity according to defined values
- Evaluation of pharmacokinetics (Serum levels of Salicylate/acetylsalicylic acid, clopidogrel-active metabolite, prasugrel-active metabolite, ticagrelor active-metabolite) [on average 3 days]
Serum levels of Salicylate/acetylsalicylic acid, clopidogrel-active metabolite, prasugrel-active metabolite, ticagrelor active-metabolite
- intensive care unit mortality [maximum 90 days]
discharge of ICU
- comparison of hemodynamically stable vs unstable ((defined by serum lactate>2.1mmol/l, need for circulatory support) [maximum 3 days]
hemodynamically stable vs unstable (defined by serum lactate>2.1mmol/l, need for circulatory support)
- major bleeding (defined by TIMI-TRITON-38 criteria) [average of 2 weeks within inclusion]
assessment of major bleeding incidences defined by TIMI-TRITON-38 criteria
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18years of age
-
admittance to an intensive care unit
Exclusion Criteria:
-
recent surgery
-
active bleeding
-
known coagulation disorders
-
discretion of the physician
-
terminal illness (anticipated life expectancy < 3months; e.g. due to cancer)
-
pregnancy
-
<20000 platelets
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | General Hospital | Vienna | Austria | 1090 |
Sponsors and Collaborators
- Medical University of Vienna
Investigators
- Principal Investigator: Bernd Jilma, Ao. Univ.-Prof. Dr. med, Medical University of Vienna, Department of Clinical Pharmacology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HTPR-ICU
- 2012-002226-76